Welcome to our dedicated page for Arcturus Therape news (Ticker: ARCT), a resource for investors and traders seeking the latest updates and insights on Arcturus Therape stock.
Arcturus Therapeutics Holdings Inc. (ARCT) is a clinical-stage RNA medicines company pioneering novel therapeutics and vaccines through its proprietary delivery platforms. This news hub provides investors and researchers with timely updates on the company's progress in developing self-amplifying mRNA (sa-mRNA) vaccines and rare disease treatments.
Access official press releases covering regulatory milestones, clinical trial developments, and strategic partnerships. Our curated collection includes updates on the LUNAR® delivery system's applications, STARR® mRNA technology advancements, and global collaborations like the ARCALIS joint venture in Japan.
Key updates include earnings reports, research publications, manufacturing expansions, and patent grants. Bookmark this page for direct access to primary source materials about ARCT's work in nucleic acid therapeutics, including programs targeting liver disorders, respiratory diseases, and infectious disease prevention.
For stakeholders tracking RNA medicine innovation, this repository offers organized chronological updates without promotional commentary. Check regularly for verified information about clinical-stage candidates and technology licensing agreements that demonstrate Arcturus' position in the biotechnology sector.
Arcturus Therapeutics (NASDAQ:ARCT), a commercial mRNA medicines company specializing in liver and respiratory rare disease therapeutics and infectious disease vaccines, has announced its participation in four upcoming investor conferences in September 2025.
The company will participate in fireside chats at Citi's Biopharma Back to School Conference (Sept 2), Wells Fargo Healthcare Conference (Sept 3), and Cantor Global Healthcare Conference (Sept 5). Additionally, Arcturus will deliver a presentation at the H.C. Wainwright Global Investment Conference (Sept 9).
Arcturus Therapeutics (NASDAQ:ARCT) reported Q2 2025 financial results and pipeline updates. Key highlights include: Q2 revenue of $28.3M (down from $49.9M in Q2 2024) and net loss of $9.2M ($0.34 per share). The company maintains a strong cash position of $253.4M, extending runway into 2028.
Pipeline progress includes: Cystic fibrosis (ARCT-032) Phase 2 interim data from nine participants expected September 2025; OTC deficiency (ARCT-810) showed positive Phase 2 results with Phase 3 planning in H1 2026; KOSTAIVE® regulatory submissions advancing globally; and Seasonal flu vaccine (ARCT-2138) demonstrated positive Phase 1 results in both young and older adults.
Arcturus Therapeutics (NASDAQ:ARCT), a commercial mRNA medicines company specializing in infectious disease vaccines and rare diseases, has scheduled its second quarter 2025 financial results announcement. The company will release its Q2 results on Monday, August 11, 2025, after market close.
A conference call and webcast will follow at 4:30 PM Eastern Time the same day. Investors can access the call via domestic (1-800-274-8461) or international (1-203-518-9814) numbers using the conference ID "ARCTURUS".
Arcturus Therapeutics (NASDAQ:ARCT), a commercial mRNA medicines company specializing in infectious disease vaccines and rare diseases, has announced its participation in two upcoming investor conferences.
The company will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on July 29, 2025, at 12:40 p.m. ET, and deliver a presentation at the CG 45th Annual Growth Conference on August 12, 2025, at 8:30 a.m. ET.
Arcturus Therapeutics (Nasdaq: ARCT), a commercial mRNA medicine company specializing in infectious disease vaccines and liver and respiratory rare diseases, has announced its participation in two upcoming investor conferences in June 2025:
- Jefferies Global Healthcare Conference: Presentation scheduled for Wednesday, June 4, 2025, at 4:20 p.m. ET
- Goldman Sachs Annual Global Healthcare Conference: Fireside Chat scheduled for Monday, June 9, 2025, at 3:20 p.m. ET
Arcturus Therapeutics (Nasdaq: ARCT), a commercial messenger RNA medicines company specializing in infectious disease vaccines and liver and respiratory rare diseases, has scheduled its first quarter 2025 financial results announcement. The company will release its financial results for the quarter ended March 31, 2025, after market close on Monday, May 12, 2025.
A conference call and webcast will follow at 4:30 PM Eastern Time on the same day. Investors can access the call through domestic (1-800-267-6316) or international (1-203-518-9783) lines using the Conference ID: ARCTURUS.
Arcturus Therapeutics (Nasdaq: ARCT) has received Fast Track Designation from the U.S. FDA for its self-amplifying mRNA vaccine candidate ARCT-2304, targeting pandemic influenza A virus H5N1. The designation, granted for vaccines addressing serious conditions, will expedite the development and review process through enhanced FDA communication, priority review eligibility, and potential rolling review.
The Phase 1 clinical study for ARCT-2304 commenced in November 2024. The vaccine utilizes Arcturus' proprietary STARR® technology platform for next-generation mRNA vaccines. The project is fully supported by federal funds from the Department of Health and Human Services, specifically through BARDA under contract number 75A50122C0007.
FAQ
What is the current stock price of Arcturus Therape (ARCT)?
What is the market cap of Arcturus Therape (ARCT)?
